Cargando…
A recombinant Mycobacterium smegmatis-based surface display system for developing the T cell-based COVID-19 vaccine
The immune escape mutations of SARS-CoV-2 variants emerged frequently, posing a new challenge to weaken the protective efficacy of current vaccines. Thus, the development of novel SARS-CoV-2 vaccines is of great significance for future epidemic prevention and control. We herein reported constructing...
Autores principales: | Wen, Ziyu, Fang, Cuiting, Liu, Xinglai, Liu, Yan, Li, Minchao, Yuan, Yue, Han, Zirong, Wang, Congcong, Zhang, Tianyu, Sun, Caijun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012901/ https://www.ncbi.nlm.nih.gov/pubmed/36785935 http://dx.doi.org/10.1080/21645515.2023.2171233 |
Ejemplares similares
-
Booster vaccination is required to elicit and maintain COVID-19 vaccine-induced immunity in SIV-infected macaques
por: Li, Pingchao, et al.
Publicado: (2023) -
Structure-based design of oligomeric receptor-binding domain (RBD) recombinant proteins as potent vaccine candidates against SARS-CoV-2
por: Zhang, Ting, et al.
Publicado: (2023) -
Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice
por: Li, Xingxing, et al.
Publicado: (2022) -
Tracking trends in COVID-19 vaccines based on 47 different vaccines: A bibliometric review
por: Tao, Zhongbin, et al.
Publicado: (2023) -
An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen
por: Wang, Xinling, et al.
Publicado: (2023)